| Literature DB >> 23752358 |
Cai-Juan Zheng1, Chang-Lun Shao, Lu-Yong Wu, Min Chen, Kai-Ling Wang, Dong-Lin Zhao, Xue-Ping Sun, Guang-Ying Chen, Chang-Yun Wang.
Abstract
One new phenylalanine derivative 4'-OMe-asperphenamate (1), along with one known phenylalanine derivative (2) and two new cytochalasins, aspochalasin A1 (3) and cytochalasin Z24 (4), as well as eight known cytochalasin analogues (5-12) were isolated from the fermentation broth of Aspergillus elegans ZJ-2008010, a fungus obtained from a soft coral Sarcophyton sp. collected from the South China Sea. Their structures and the relative configurations were elucidated using comprehensive spectroscopic methods. The absolute configuration of 1 was determined by chemical synthesis and Marfey's method. All isolated metabolites (1-12) were evaluated for their antifouling and antibacterial activities. Cytochalasins 5, 6, 8 and 9 showed strong antifouling activity against the larval settlement of the barnacle Balanus amphitrite, with the EC50 values ranging from 6.2 to 37 μM. This is the first report of antifouling activity for this class of metabolites. Additionally, 8 exhibited a broad spectrum of antibacterial activity, especially against four pathogenic bacteria Staphylococcus albus, S. aureus, Escherichia coli and Bacillus cereus.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23752358 PMCID: PMC3721221 DOI: 10.3390/md11062054
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of compounds 1–12.
NMR spectroscopic data (600/150 MHz, DMSO-d6) for compound 1.
| Position | 1H ( | 13C | Position | 1H ( | 13C |
|---|---|---|---|---|---|
| 1 | - | 134.2, C | 8′ | 4.62, m | 50.4, CH |
| 2 | 7.23, m | 129.4, CH | 9′ | 4.52, dd (10.8, 4.2) | 65.4, CH2 |
| 3 | 7.38, m | 128.8, CH | 4.05, dd (10.8, 3.0) | ||
| 4 | 7.24, m | 127.2, CH | 10′ | 6.71, d (8.4) | - |
| 5 | 7.23, m | 128.8, CH | 1″ | - | 133.4, C |
| 6 | 7.38, m | 129.4, CH | 2″ | 7.65, m | 127.2, CH |
| 7 | 3.22, dd (14.4, 6.6) | 37.4, CH2 | 3″ | 7.30, m | 128.5, CH |
| 3.16, dd (14.4, 6.6) | 4″ | 7.50, m | 132.1, CH | ||
| 8 | 4.88, m | 55.2, CH | 5″ | 7.30, m | 128.5, CH |
| 9 | - | 172.1, C | 6″ | 7.65, m | 126.9, CH |
| 10 | 6.59, d (6.6) | - | 7″ | - | 167.5, C |
| 1′ | - | 137.3, C | 1′″ | - | 137.2, C |
| 2′ | 7.10, d (8.4) | 130.3, CH | 2′″ | 7.70, m | 127.1, CH |
| 3′ | 6.81, d (8.4) | 114.3, CH | 3′″ | 7.30, m | 128.5, CH |
| 4′ | - | 158.9, C | 4′″ | 7.42, m | 131.5, CH |
| 5′ | 6.82, d (8.4) | 114.3, CH | 5′″ | 7.30, m | 128.5, CH |
| 6′ | 7.12, d (8.4) | 130.3, CH | 6′″ | 7.70, m | 127.1, CH |
| 7′ | 3.00, dd (13.2, 6.6) | 36.7, CH2 | 7′″ | - | 166.7, C |
| 2.89, dd (13.2, 8.4) | 4′-OCH3 | 3.74, s | 54.6, CH3 |
Figure 21H-1H COSY correlations and key heteronuclear multiple bond correlation (HMBC) correlations of compounds 1, 3 and 4.
Figure 3The preparation of compounds 14a and 14b.
NMR spectroscopic data (600/150 MHz, CDCl3) for compounds 3 and 4.
| Position | 3 | 4 | ||
|---|---|---|---|---|
| 1H ( | 13C | 1H ( | 13C | |
| 1 | - | 172.0, C | - | 166.9, C |
| 2 | 5.93, br s | - | 6.30, br s | - |
| 3 | 3.00, m | 52.6, CH | 3.68, m | 53.6, CH |
| 4 | 2.49, dd (4.2, 3.6) | 52.6, CH | 3.04, br d (5.4) | 49.2, CH |
| 5 | 2.74, m | 35.1, CH | 2.22, m | 35.9, CH |
| 6 | - | 141.2, C | - | 57.2, C |
| 7 | 5.37, br s | 122.5, CH | 2.74, d (5.4) | 60.8, CH |
| 8 | 3.43, d (10.8) | 42.1, CH | 2.99, d (10.8, 5.4) | 47.0, CH |
| 9 | - | 86.8, C | - | 85.2, C |
| 10 | 1.96, m | 46.4, CH2 | 2.86, dd (12.6, 8.4) | 45.1, CH2 |
| 1.57, m | 2.77, dd (12.6, 6.6) | |||
| 11 | 1.21, d (6.6) | 14.3, CH3 | 0.93, d (6.6) | 12.7, CH3 |
| 12 | 1.78, br s | 20.3, CH3 | 1.17, br s | 19.5, CH3 |
| 13 | 6.00, d (10.8) | 125.6, CH | 6.03, dd (13.2, 10.8) | 124.2, CH |
| 14 | - | 136.2, C | 5.21, ddd (13.2, 10.8, 3.6) | 138.8, CH |
| 15 | 2.68, m | 37.2, CH2 | 2.11, m | 44.1, CH2 |
| 2.39, m | 2.08, m | |||
| 16 | 2.69, m | 35.5, CH2 | 1.27, m | 29.3, CH |
| 2.45, m | ||||
| 17 | - | 212.7, C | 1.76, dd (13.2, 1.8) | 53.8, CH2 |
| 1.68, dd (13.2, 5.4) | ||||
| 18 | 5.00, ddd (10.8, 3.6, 3.6) | 74.0, CH | - | 72.8, C |
| 19 | 2.10, m | 29.1, CH2 | 7.11, d (15.6) | 159.1, CH |
| 1.53, m | ||||
| 20 | 2.65, m | 31.4, CH2 | 5.69, d (15.6) | 119.1, CH |
| 2.44, m | ||||
| 21 | - | 171.8, C | - | 172.8, C |
| 22 | 1.19, m | 25.6, CH | 1.03, d (6.6) | 27.1, CH3 |
| 23 | 0.93, d (6.6) | 21.0, CH3 | 1.33, s | 22.0, CH3 |
| 24 | 0.90, d (6.6) | 23.9, CH3 | - | - |
| 25 | 1.80, br s | 15.9, CH3 | - | - |
| 1′ | - | - | - | 137.0, C |
| 2′/6′ | - | - | 7.15, br d (7.2) | 129.4, CH |
| 3′/5′ | - | - | 7.30, m | 129.0, CH |
| 4′ | - | - | 7.25, m | 127.1, CH |
| 18-OH | 3.56, d (3.6) | |||
Figure 4Key NOESY correlations of compound 3.
Antibacterial activity for compounds 1, 2, 5, 8 and 10.
| Compound | MIC (μM) | |||
|---|---|---|---|---|
|
|
|
|
| |
| 10 | >20 | >20 | >20 | |
| 10 | >20 | >20 | >20 | |
| 20 | 10 | >20 | >20 | |
| 10 | 10 | 10 | 10 | |
| 20 | >20 | >20 | >20 | |
| Ciprofloxacin a | 0.30 | 0.30 | 0.60 | 1.20 |
a Ciprofloxacin was used as a positive control.